Hispolon Protects Against Acute Liver Damage in the Rat by Inhibiting Lipid Peroxidation, Proinflammatory Cytokine, and Oxidative Stress and Downregulating the Expressions of INOS, COX-2, and MMP-9
Overview
Authors
Affiliations
The hepatoprotective potential of hispolon against carbon tetrachloride (CCl(4))-induced liver damage was evaluated in preventive models in rats. Male rats were intraperitoneally treated with hispolon or silymarin once daily for 7 consecutive days. One hour after the final hispolon or silymarin treatment, the rats were injected with CCl(4). Administration with hispolon or silymarin significantly decreased the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in serum and increased the activities of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), and glutathione (GSH) content and decreased the malondialdehyde (MDA) content in liver compared with CCl(4)-treated group. Liver histopathology also showed that hispolon reduced the incidence of liver lesions induced by CCl(4). In addition, hispolon decreased nitric oxide (NO) production and tumor necrosis factor (TNF-α), inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) activation in CCl(4)-treated rats. We also examined the involvement of matrix metalloproteinase (MMP)-9 in the development of CCl(4)-induced liver damage in rats. Hispolon inhibited the expression of MMP-9 protein, indicating that MMP-9 played an important role in the development of CCl(4)-induced rat liver damage. Therefore, we speculate that hispolon protects rats from liver damage through their prophylactic redox balancing ability and anti-inflammation capacity.
Yang C, Li C, Sie Y, Chen L, Yuan Y, Hou W Bot Stud. 2024; 65(1):38.
PMID: 39692936 PMC: 11655744. DOI: 10.1186/s40529-024-00443-x.
The clinical anti-inflammatory effects and underlying mechanisms of silymarin.
Zhao Y, Zhou Y, Gong T, Liu Z, Yang W, Xiong Y iScience. 2024; 27(11):111109.
PMID: 39507256 PMC: 11539592. DOI: 10.1016/j.isci.2024.111109.
Research Progress of Bioactive Components in spp.
Lu J, Su M, Zhou X, Li D, Niu X, Wang Y Molecules. 2024; 29(6).
PMID: 38542832 PMC: 10976032. DOI: 10.3390/molecules29061195.
Sadeghi Ivraghi M, Zamanian M, Gupta R, Achmad H, Alsaab H, Hjazi A CNS Neurosci Ther. 2023; 30(3):e14473.
PMID: 37904726 PMC: 10916451. DOI: 10.1111/cns.14473.
Elmetwalli A, Diab T, Albalawi A, El-Naggar S, El-Far A, Ghedan A Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(10):2501-2517.
PMID: 37145126 PMC: 10497687. DOI: 10.1007/s00210-023-02470-0.